Clinical data | |
---|---|
Other names | NW-3509; NW-3509A |
Routes of administration | oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C16H26N2O2 |
Molar mass | 278.396 g·mol−1 |
3D model ( JSmol) | |
| |
|
Evenamide ( INN ) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. [1] [2] [3] [4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. [3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015. [5]
In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023. [6]
Clinical data | |
---|---|
Other names | NW-3509; NW-3509A |
Routes of administration | oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C16H26N2O2 |
Molar mass | 278.396 g·mol−1 |
3D model ( JSmol) | |
| |
|
Evenamide ( INN ) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. [1] [2] [3] [4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. [3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015. [5]
In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023. [6]